Physician practices and attitudes towards atopic dermatitis in Latin America: A cross-sectional study.
Atopic
Dermatitis
Eczema
Latin America
Management
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
17
04
2023
revised:
28
09
2023
accepted:
05
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
The prevalence of atopic dermatitis (AD) is increasing in developing countries. Different worldwide guidelines have been proposed, but their applicability for AD specialists in Latin American (LA) countries is unknown. The objective of this study was to explore the medical approach to treating AD in LA countries. The study population comprised AD specialists (allergists and dermatologists). They completed an electronic survey containing questions about the health system, diagnostic criteria, and pharmacotherapy approach to treating AD. The survey was constructed and validated by the Atopic Dermatitis Committee of the Latin American Society of Allergy Asthma and Immunology (SLAAI) in Spanish and Portuguese. Each member was responsible for distributing the questionnaire through different networks in their respective countries. A total of 284 AD specialists from 13 LA countries completed the questionnaire; among them, 67% were allergists and 33% were dermatologists. Less than 50% of the AD specialists strictly followed guideline recommendations. Among the AD specialists, the European and North American guidelines were more frequently used, and only 16% followed LA guidelines. Dermatologists used the local guidelines less frequently than allergists. Most physicians did not routinely use AD assessment tools (55%). The frequency of the diagnostic tests depends on symptom severity. The availability of some systemic treatments, such as biologics and Janus Kinase (JAK) inhibitors, is not universal in all LA countries. There were marked differences between the specialists, and these differences seemed to be affected by their specialty and each country's healthcare system. New AD education strategies that consider the particularities of the region could allow patients to be more accurately managed. AD assessment tools may provide a way to enhance AD treatment and allow for shared decision-making, patient empowerment, and standardized care.
Sections du résumé
Background
UNASSIGNED
The prevalence of atopic dermatitis (AD) is increasing in developing countries. Different worldwide guidelines have been proposed, but their applicability for AD specialists in Latin American (LA) countries is unknown.
Objective
UNASSIGNED
The objective of this study was to explore the medical approach to treating AD in LA countries.
Methods
UNASSIGNED
The study population comprised AD specialists (allergists and dermatologists). They completed an electronic survey containing questions about the health system, diagnostic criteria, and pharmacotherapy approach to treating AD. The survey was constructed and validated by the Atopic Dermatitis Committee of the Latin American Society of Allergy Asthma and Immunology (SLAAI) in Spanish and Portuguese. Each member was responsible for distributing the questionnaire through different networks in their respective countries.
Results
UNASSIGNED
A total of 284 AD specialists from 13 LA countries completed the questionnaire; among them, 67% were allergists and 33% were dermatologists. Less than 50% of the AD specialists strictly followed guideline recommendations. Among the AD specialists, the European and North American guidelines were more frequently used, and only 16% followed LA guidelines. Dermatologists used the local guidelines less frequently than allergists. Most physicians did not routinely use AD assessment tools (55%). The frequency of the diagnostic tests depends on symptom severity. The availability of some systemic treatments, such as biologics and Janus Kinase (JAK) inhibitors, is not universal in all LA countries.
Conclusion
UNASSIGNED
There were marked differences between the specialists, and these differences seemed to be affected by their specialty and each country's healthcare system. New AD education strategies that consider the particularities of the region could allow patients to be more accurately managed. AD assessment tools may provide a way to enhance AD treatment and allow for shared decision-making, patient empowerment, and standardized care.
Identifiants
pubmed: 37965095
doi: 10.1016/j.waojou.2023.100832
pii: S1939-4551(23)00092-3
pmc: PMC10641564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100832Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest with this article.
Références
Br J Dermatol. 2018 May;178(5):e332-e341
pubmed: 29672835
Rev Alerg Mex. 2014 Jul-Sep;61(3):178-211
pubmed: 25177854
Dermatitis. 2022 Nov-Dec 01;33(6S):S83-S91
pubmed: 35648105
Rev Alerg Mex. 2015 Jul-Sep;62(3):226-33
pubmed: 26239333
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1904-1926
pubmed: 36056736
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1409-1431
pubmed: 35980214
Br J Dermatol. 2021 Oct;185(4):781-786
pubmed: 33817779
Rev Alerg Mex. 2017 Jul-Sep;64(3):260-269
pubmed: 29046024
Life (Basel). 2021 Nov 29;11(12):
pubmed: 34947845
Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151
pubmed: 31034875
Psychol Res Behav Manag. 2018 Jul 31;11:289-298
pubmed: 30104911
Dermatol Ther (Heidelb). 2021 Oct;11(5):1521-1540
pubmed: 34449071
Dermatol Ther (Heidelb). 2023 Feb;13(2):399-416
pubmed: 36562945
Ann Dermatol. 2014 Feb;26(1):26-34
pubmed: 24648683
Rev Alerg Mex. 2019 Oct-Dec;66(4):426-455
pubmed: 32105426
Clin Exp Dermatol. 2018 Jun;43(4):375-379
pubmed: 29314180
J Am Acad Dermatol. 2014 Feb;70(2):338-51
pubmed: 24290431
J Investig Allergol Clin Immunol. 2010;20(4):311-23
pubmed: 20815309
Rev Alerg Mex. 2018 Oct-Dec;65(4):389-399
pubmed: 30602209